prepared in dimethylsulfoxide as 1000 mM stock solutions and kept at 4°C. 3TC was from Moravek Biochemicals (Brea, CA, U.S.A.) and served as the positive control. Dilutions of the drugs were performed on the day of medium change. The final concentration of dimethylsulfoxide in the samples was less than 0.01% (v/v).
Cell Culture and Treatment The human HBV-transfected cell line HepG2.2.15 24) was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (both from Gibco-Invitrogen, Carlsbad, CA, U.S.A.), 100 unit/ml penicillin, 100 mg/ml streptomycin, and 200 mg/ml G418 (all from Sigma, St. Louis, MO, U.S.A.) at 37°C in a humidified incubator with 5% CO 2 . Cells were maintained for 24 h before treatment to reach confluence. The confluent HepG2.2.15 cells were treated with cinobufacini, bufalin, cinobufagin, or 3TC at various concentrations in serum-free medium for 3 d or 6 d. The culture medium was replaced with a fresh one on d 3, with or without (negative control conditions) different concentrations of drugs or 3TC during the 6-d experiment.
Cytotoxicity Assay HepG2.2.15 cells were seeded in 96-well plates at a density of 1.5ϫ10 4 per well and respectively treated with cinobufacini (1, 10, 20 , 50, 100, or 215 mg/ml), bufalin (10 Measurement of HBV Antigens HepG2.2.15 cells were seeded in 6-well plates at a density of 4.5ϫ10 5 per well for measurement of HBV antigens, HBV DNA, and HBV RNA. After incubation with various concentrations of cinobufacini, bufalin, cinobufagin, or 3TC for 3 or 6 d, the culture medium was collected, cell debris was removed, and the result was stored at Ϫ70°C until analysis. Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core-related antigen (HBcrAg) in culture supernatants of HepG2.2.15 cells were respectively measured with a Lumipulse ® II or I kit or HBcrAg kit (Fuji Rebio, Tokyo, Japan). These kits use a method of chemiluminescent enzyme immunoassay (CLEIA) based on the chemiluminescent capture of specific antigen-antibody reactions.
Quantification of HBV DNA in the Culture Medium The HBV viral load in culture supernatants of HepG2.2.15 cells was quantified with a HBV DNA quantitative kit (SRL, Tokyo, Japan). This kit is based on transcription-mediated amplification and hybridization protection assay. 25) Briefly, a mixture of 10 ml of cell culture supernatants or amplification standards, Sample Diluent I, Sample Diluent II, and Primer Reagent and 50 ml of oil were placed in a reaction tube. The tube was heated at 95°C for 10 min and then incubated at 37°C for 5 min. Neutralization reagent and reconstituted amplification reagent solution were added and the reaction mixture was incubated at 37°C for 3 h. RNA amplicons were detected with a hybridization protection assay. The measurement range was 3.7-8.7 log genome equivalent/ml (LGE/ ml).
Determination of HBV RNA Total RNA was isolated ) was used to amplify and detect DNA during the reaction. Thermal cycling parameters for the HBV core region and GAPDH consisted of a hot start for 2 min at 94°C followed by 40 cycles of 94°C for 15 s, 60°C for 30 s, and then 72°C for 40 s. Thermal cycling parameters for the HBV surface region consisted of a hot start for 2 min at 94°C followed by 45 cycles of 94°C for 15 s, 58°C for 30 s, and then 72°C for 30 s. Specificity of the PCR products was verified by melting curve analysis and agarose gel electrophoresis.
Statistical Analysis All the items determined in this study were repeated at least three times, and the results were expressed as meanϮS.D. Statistical significance was determined using analysis of variance (ANOVA) or a rank sum test. Differences were considered significant at pϽ0.05.
RESULTS

Cytotoxic Effects of Cinobufacini, Bufalin, and Cinobufagin
The viabilities of the HepG2.2.15 cells in the presence of various concentrations of cinobufacini, bufalin, and cinobufagin were examined with a MTT assay. The results showed that cinobufacini concentrations below 20 mg/ml, bufalin concentrations below 10 Ϫ2 mM, and cinobufagin concentrations below 10 Ϫ1 mM had no significant toxicity to HepG2.2.15 cells (Fig. 2) . Cinobufacini, bufalin, and cinobufagin significantly inhibited the growth of HepG2.2.15 cells at concentrations above 20 mg/ml, 10 Ϫ2 mM, and 10 Ϫ1 mM, respectively. The cytotoxicity of these drugs was examined to determine the treatment concentrations in the following HepG2.2.15 cell culture experiments.
Effects of Cinobufacini on HBV Antigens and DNA In this anti-HBV assay, HepG2.2.15 cells were treated with different concentrations of cinobufacini for 3 or 6 d. On d 3, cinobufacini at a concentration of 1 mg/ml had no activity against HBV virological markers. However, on d 6, cinobufacini at a concentration of 1 mg/ml significantly reduced the secretion of HBsAg, HBeAg, and HBcrAg in the culture medium (Table 1 ). This concentration of cinobufacini exhib-ited more potent activity than the positive control 3TC (100 mg/ml) in terms of the inhibition of HBV antigen secretion. It respectively decreased secretion of HBsAg, HBeAg, and HBcrAg by 29.58, 32.87, and 42.52% while 3TC at 100 mg/ml respectively reduced secretion of these antigens by 21.88, 20.81, and 17.38%. Cinobufacini at 20 mg/ml also inhibited secretion of HBV antigens. There were no significant differences between cinobufacini treatment and the control in terms of the HBV DNA levels in the culture medium.
Effects of Bufalin on HBV Antigens and DNA Treatment of HepG2.2.15 cells with bufalin resulted in a reduction of HBsAg, HBeAg, and HBcrAg secretion (Table 2) . After treatment for 6 d, bufalin at a concentration of 10 Ϫ4 mM significantly inhibited secretion of HBcrAg at a rate of 19.58%. This concentration of bufalin was more potent than the positive control 3TC at inhibiting HBcrAg secretion. Based on this analysis, bufalin has greater inhibitory activity with respect to HBeAg than to HBsAg. Like cinobufacini, bufalin exhibited no inhibitory effect on HBV DNA in culture medium ( Table 2) .
Effects of Cinobufagin on HBV Antigens and DNA After 3 or 6 d of incubation with cinobufagin, secretion of HBeAg and HBcrAg in the culture medium was slightly less than that with the control (Table 3) . Moreover, cinobufagin at a concentration of 10 Ϫ3 mM on d 3 exhibited the same potent activity as the positive control 3TC (100 mg/ml) in terms of the inhibition of HBeAg secretion. Cinobufagin was also found to have relatively greater inhibition of HBeAg than HBsAg. Consistent with the inhibitory effects of cinobufacini and bufalin, cinobufagin treatment led to no significant antiviral activity in HBV DNA release to the culture medium in comparison to the control (Table 3) .
Effects of Cinobufacini, Bufalin, and Cinobufagin on HBV mRNA Expression To determine if the effects of cinobufacini, bufalin, and cinobufagin on HBsAg, HBeAg, and HBcrAg secretion were induced by decreases in HBV RNA levels, real-time PCR analysis was performed using total RNA isolated from HepG2.2.15 cells. When treated with cinobufacini at a concentration of 1 mg/ml for 6 d, inhibition of HBV mRNA was observed with a 56.08% reduction in the HBV surface/GAPDH mRNA ratio and a 65.12% reduction in the HBV core/GAPDH mRNA ratio in comparison to controls (Fig. 3) . Similarly, incubation with bufalin at 10 Ϫ4 mM and cinobufagin at 10 Ϫ3 mM led to significant reductions in HBV mRNA from the surface and core regions. These results showed that the HBV mRNA expression was markedly inhibited in comparison to the control when HepG2.2.15 cells were treated with cinobufacini, bufalin, or cinobufagin at lower concentrations. These findings revealed that the inhibitory effects of cinobufacini, bufalin, and cinobufagin on the secretion of HBV antigens would be induced by the specific inhibition of HBV mRNA expression. 
DISCUSSION
Cinobufacini, a Chinese medicine derived from the toad skin of Bufo bufo gargarizans Cantor (Bufonidae), has long been used in the treatment of hepatitis B in China. 18, 19, 26) Therefore, cinobufacini has been considered to have the efficacy in the management of HBV infection. In the present study, the anti-HBV activity of cinobufacini was evaluated in the HepG2.2.15 cell line. Cinobufacini at a concentration of 1 mg/ml exhibited more potent activity than the positive control 3TC (100 mg/ml) in terms of the inhibition of HBV antigen secretion after treatment of HepG2.2.15 cells for 6 d.
It inhibited the secretion of HBsAg, HBeAg, and HBcrAg by 29.58, 32.87, and 42.52%, respectively, while 3TC at 100 mg/ml decreased secretion of these three antigens by 21.88, 20.81, and 17.38%, respectively. This effect of 3TC was consistent with that noted in a previous report. 27) Moreover, no cytotoxicity was observed with cinobufacini at 1 mg/ml. These results clearly revealed that cinobufacini had anti-HBV properties and that its inhibitory activities were not induced by cytotoxicity.
Many reports have noted that the main pharmacologically active components of cinobufacini include bufalin and cinobufagin. 20, 21) Therefore, the present study also analyzed the anti-HBV activities of bufalin and cinobufagin. The concentrations of bufalin and cinobufagin in cinobufacini at 20 g/ml are 12.84 mg/ml and 6.133 mg/ml, respectively. 28) Thus, 1 mg/ml of cinobufacini contained 6.42ϫ10
Ϫ7 mg/ml of bufalin, which was lower than 10 Ϫ4 mM (3.87ϫ10 Ϫ5 mg/ml) of pure bufalin. That is to say, although the bufalin level in cinobufacini at 1 mg/ml was less than bufalin at 10 Ϫ4 mM, the effect of cinobufacini at 1 mg/ml was more potent than that of bufalin at 10 Ϫ4 mM in terms of inhibiting HBV antigen secretion. Similarly, the inhibitory activity of cinobufacini at 1 mg/ml (containing 3.07ϫ10
Ϫ7 mg/ml of cinobufagin) was greater than cinobufagin at 10 Ϫ3 mM (4.43ϫ10 Ϫ4 mg/ml). These data strongly suggested that cinobufacini was more potent than its components bufalin and cinobufagin in terms of inhibiting HBV.
The anti-HBV activity of bufalin has been reported. 23) October 2010 1731 This report only detected HBsAg among HBV antigens and showed that treatment with bufalin for 21 d decreased HBsAg secretion and increased HBV DNA level in the culture medium. The discrepancy in the anti-HBV effect of this report and the present study could be attributed to different time course of treatment and different bufalin concentrations. The effects of cinobufacini, bufalin, and cinobufagin at lower concentrations were respectively more potent than those of these three drugs at higher concentrations in terms of inhibiting HBV antigen secretion. This result could be explained by the cytotoxic effects that were induced by these three drugs at some concentrations, such as 8% of toxic effect induced by cinobufacini at 20 mg/ml on d 6. The impairment of cells might affect the production and release of HBV particles, which were decreased or increased.
In clinical application, the side effects that may be related to cinobufacini include hematologic, gastrointestinal, mucocutaneous, and cardiovascular symptoms, but these adverse effects are mild. 18, 29) A clinical study demonstrated that 73% of patients administered with cinobufacini had no toxicities greater than grade I and no grade III or IV toxicities were observed. 30) Moreover, although cinobufacini contains cardiac glycosides (bufalin, cinobufagin, etc.), significant cardiac toxicity was not observed. 18, 30) The results of present study suggested that cinobufacini at lower concentrations without toxicity possessed potent anti-HBV activity. Therefore, the anti-HBV effect induced by cinobufacini could be achieved without toxicity in humans.
In the present study, cinobufacini, bufalin, and cinobufagin inhibited HBV antigen secretion. These roles may take place at the transcription and post-transcription levels. 31) Therefore, the HBV mRNA level was determined in HepG2.2.15 cells. The results revealed that HBV antigen inhibition by cinobufacini, bufalin, and cinobufagin was attributed to the specific inhibition of HBV mRNA expression. The decreases in HBV mRNA levels may be induced by the decreased synthesis and the increased degradation of HBV mRNA, which is regulated by enhancers and promoters of HBV, several nuclear hormone receptors and their physiological regulators, RNA-binding proteins, and nuclear RNases, etc. 32) Therefore, the inhibition of HBV mRNA expression by cinobufacini, bufalin, and cinobufagin might be due to the effects of these three drugs on these cis elements, nuclear hormone receptors and their physiological regulators, RNAbinding proteins, and RNases.
In conclusion, the present study demonstrated that cinobufacini possessed potent anti-HBV activity in vitro. It was more effective than its components bufalin and cinobufagin at inhibiting the secretion of HBV antigens. These inhibitory roles of cinobufacini, bufalin, and cinobufagin might take place at the transcription and post-transcription levels. The present findings suggested that cinobufacini could effectively inhibit HBV antigen secretion in vitro. Therefore, cinobufacini warrants further investigation.
